Earnings ReportVimian delivered a weak Q1 report, with net sales increasing only 4% y-o-y to EUR 91.3m, missing consensus by 3%.
Financial PerformanceAdjusted EBITA declined 8% y-o-y to EUR 24.1m, missing consensus estimates by 8% due to the smaller AOP in MedTech.
Organic GrowthOrganic growth amounted to just 1% on a group level, driven by a 12% decline in MedTech as a result of the company's decision to reduce the annual ordering program.